Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPR3 | P17342 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | LOX | P28300 | 1/20 | 0.30 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL828347 | 0.91 | RAB9A (0.37) | RAB9ASSTR4ALDH1A1GRM2AAK1 | |
| SCHEMBL828345 | 0.89 | RAB9A (0.36) | RAB9ASSTR4ALDH1A1GRM2AAK1 | |
| SCHEMBL828279 | 0.86 | ALDH1A1 (0.39) | RAB9AALDH1A1NPC1LMNAMAPK14 | |
| SCHEMBL828683 | 0.84 | RAB9A (0.38) | RAB9ASSTR4ALDH1A1GRM2NPC1 | |
| SCHEMBL828280 | 0.83 | RAB9A (0.39) | RAB9ASSTR4ALDH1A1GRM2AAK1 | |
| SCHEMBL828680 | 0.83 | RAB9A (0.36) | RAB9ASSTR4ALDH1A1GRM2AAK1 | |
| SCHEMBL829906 | 0.80 | SSTR4 (0.33) | SSTR4ALDH1A1GRM2AAK1SLC6A9 | |
| SCHEMBL828285 | 0.80 | SSTR4 (0.33) | SSTR4ALDH1A1GRM2AAK1SLC6A9 | |
| SCHEMBL828344 | 0.78 | POLB (0.42) | RAB9ALMNAPOLBMAPK14 | |
| SCHEMBL860537 | 0.78 | ELANE (0.33) | RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| US-9617221-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-9617221-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2013-02-21 | — | — | US | disclosed |
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2013-02-21 | — | — | US | disclosed |
| US-8143294-B2 | 2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors | BURNET MICHAEL (DE) | 2012-03-27 | — | — | US | disclosed |
| US-8143294-B2 | 2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors | BURNET MICHAEL (DE) | 2012-03-27 | — | — | US | disclosed |
| US-8143294-B2 | 2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors | BURNET MICHAEL (DE) | 2012-03-27 | — | — | US | disclosed |
| WO-2011100769-A2 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2011-08-18 | — | — | WO | disclosed |
| US-20090270462-A1 | 2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SYNOVO GMBH (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270462-A1 | 2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SYNOVO GMBH (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270462-A1 | 2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SYNOVO GMBH (DE) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | MAP3K10, MAP3K12, MAP3K20 | RAB9A 2039/4885SSTR4 4344/4885ALDH1A1 4439/4885 |
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | MAP3K10, MAP3K12, MAP3K20 | RAB9A 2039/4885SSTR4 4344/4885ALDH1A1 4439/4885 |
| US-20090270462-A1 | 2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | IL2, IL2RA, IL1B | RAB9A 2338/4885SSTR4 1878/4885ALDH1A1 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.